

PRP31 Antibody - C-terminal region

Rabbit Polyclonal Antibody

Catalog # AI16120

Product Information

Application	WB
Primary Accession	Q8WWY3
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	55456

Additional Information

Gene ID	26121
Alias Symbol Other Names	PRPF31, PRP31, U4/U6 small nuclear ribonucleoprotein Prp31, Pre-mRNA-processing factor 31, Serologically defined breast cancer antigen NY-BR-99, U4/U6 snRNP 61 kDa protein, Protein 61K, hPrp31, PRPF31, PRP31
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 μ l of distilled water. Final Anti-PRP31 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Precautions	PRP31 Antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	PRPF31 (HGNC:15446)
Synonyms	PRP31
Function	Involved in pre-mRNA splicing as component of the spliceosome (PubMed: 11867543 , PubMed: 20118938 , PubMed: 28781166). Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome (PubMed: 11867543).
Cellular Location	Nucleus. Nucleus speckle. Nucleus, Cajal body. Note=Predominantly found in speckles and in Cajal bodies.
Tissue Location	Ubiquitously expressed.

Background

Involved in pre-mRNA splicing. Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome.

References

Makarova O.V.,et al.EMBO J. 21:1148-1157(2002).


Scanlan M.J.,et al.Cancer Immun. 1:4-4(2001).

Wiemann S.,et al.Genome Res. 11:422-435(2001).

Ota T.,et al.Nat. Genet. 36:40-45(2004).

Oshikawa M.,et al.Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011).

Images



Host: Rabbit
Target Name: PRP31
Sample Tissue: Jurkat Whole Cell lysates
Antibody Dilution: 1.0µg/ml

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.